Наукові праці. Кафедра інфекційних хвороб

Permanent URI for this collectionhttps://repo.knmu.edu.ua/handle/123456789/510

Browse

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression
    (2016) Llibre, Josep M.; Cozzi-Lepri, Alessandro; Pedersen, Court; Ristola, Matti; Mocrof, Amanda; Mitsura, Viktar; Maltez, Fernando; Falconer, Karolin; Beniowsk, Marek; Vullo, Vincenzo; Gamal, Hassoun; Kuzovatova, Elena; Szlavik, János; Kuznetsova, Anastasiia; Hans-Jürgen, Stellbrink; Claudine, Duvivier; Simon, Edwards; Kamilla, Laut; Roger, Paredes
    Effectiveness data of an unboosted atazanavir (ATV) with abacavir/lamivudine (ABC/3TC) switch strategy in clinical routine are scant. We evaluated treatment outcomes of ATV + ABC/3TC in pretreated subjects in the EuroSIDA cohort when started with undetectable plasma HIV-1 viral load (pVL), performing a time to loss of virological response (TLOVR <50 copies/mL) and a snapshot analysis at 48, 96, and 144 weeks. Virological failure (VF) was defined as confirmed pVL >50 copies/mL. We included 285 subjects, 67% male, with median baseline CD4 530 cells, and 44 months with pVL 50 copies/mL. The third drug in the previous regimen was ritonavir-boosted atazanavir (ATV/r) in 79 (28%), and another ritonavir-boosted protease inhibitor (PI/r) in 29 (10%). Ninety (32%) had previously failed with a PI. Proportions of people with virological success at 48/96/144 weeks were 90%/87%/88% (TLOVR) and 74%/67%/59% (snapshot analysis), respectively. The rates of VF were 8%/8%/6%. Rates of adverse events leading to study discontinuation were 0.4%/1%/2%. The multivariable adjusted analysis showed an association